Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Post time The day before yesterday 00:09

DOI: 10.1016/S1470-2045(19)30785-5

Lecia V Sequist 1, Ji-Youn Han 2, Myung-Ju Ahn 3, Byoung Chul Cho 4, Helena Yu 5, Sang-We Kim 6, James Chih-Hsin Yang 7, Jong Seok Lee 8, Wu-Chou Su 9, Dariusz Kowalski 10, Sergey Orlov 11, Mireille Cantarini 12, Remy B Verheijen 12, Anders Mellemgaard 12, Lone Ottesen 12, Paul Frewer 13, Xiaoling Ou 13, Geoffrey Oxnard

Post time The day before yesterday 00:11

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study